Irbesartan, an angiotensin II type 1 receptor blocker, inhibits colitis-associated tumourigenesis by blocking the MCP-1/CCR2 pathway

The introduction of anti-inflammatory therapies has enabled substantial improvement of disease activity in patients with inflammatory bowel diseases (IBD). However, IBD can lead to serious complications such as intestinal fibrosis and colorectal cancer. Therefore, novel therapies reducing the develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hachiya, Kensuke, Masuya, Masahiro, Kuroda, Naoki, Yoneda, Misao, Tsuboi, Junya, Nagaharu, Keiki, Nishimura, Komei, Shiotani, Takuya, Ohishi, Kohshi, Tawara, Isao, Katayama, Naoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497524/
https://www.ncbi.nlm.nih.gov/pubmed/34620946
http://dx.doi.org/10.1038/s41598-021-99412-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497524/
https://www.ncbi.nlm.nih.gov/pubmed/34620946
http://dx.doi.org/10.1038/s41598-021-99412-8

Ejemplares similares